News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BIND Therapeutics Reports Fourth Quarter And Full Year 2013 Financial Results


3/25/2014 7:29:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter and year-ended December 31, 2013.

“2013 was a transformative year for BIND as we made significant progress towards providing improved treatment options for patients with cancer,” said Scott Minick, BIND’s President and CEO.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES